ABIVAX Societe Anonyme (ABVX) to Present Phase 3 UC Data at UEG Congress, Investor Call Scheduled

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. ABIVAX Société Anonyme is one of them.

ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology company developing therapies to regulate immune responses in chronic inflammatory diseases. Its lead candidate, obefazimod (ABX464), is an oral miR-124 enhancer currently in Phase 3 trials for ulcerative colitis (UC) and Phase 2b trials for Crohn’s disease.

In September 2025, ABVX announced it would present late-breaking data from the ABTECT Phase 3 induction trials at the United European Gastroenterology (UEG) Congress in Berlin on October 6. The presentation will highlight eight-week efficacy results of obefazimod, including outcomes in patients who previously did not respond to advanced therapies. Alongside the congress, the business will host an investor call and a symposium on new treatment mechanisms for UC.

Earlier in July, the corporation reported positive topline data from two Phase 3 induction trials in moderate to severe UC. Results showed a pooled clinical remission rate 16.4% higher than placebo, with the 50 mg dose achieving a 19.3% placebo-adjusted remission rate. Based on ongoing maintenance studies, ABVX plans to submit U.S. and European regulatory applications in the second half of 2026.

To support these late-stage programs, ABIVAX Société Anonyme (NASDAQ:ABVX) strengthened its financial position with a $650 million (€554 million) public offering in July 2025. The funding extends the company’s cash runway into the fourth quarter of 2027, bolstering investor confidence as it advances obefazimod toward potential approval and commercialization.

While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.